Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2021 - 06 - 07 save search
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Published: 2021-06-07 (Crawled : 19:00) - biospace.com/
AZN | $68.38 -0.22% 2.3M
|
Health Technology
|
| O: -0.32%
H: 0.6%
C: -0.39%
fda fda approval children approval
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
Published: 2021-06-07 (Crawled : 18:00) - globenewswire.com
BIIB | $190.805 -0.71% 870K
|
Health Technology
|
| O: 3.22%
H: 58.64%
C: 34.03%
disease alzheimer treatment fda approval alzheimer’s alzheimer's disease alzheimer's
Synaptogenix Responds to FDA Approval of Aducanumab
Published: 2021-06-07 (Crawled : 16:00) - prnewswire.com
SNPX | $4.89 1.88% 9.6K
|
Professional, Scientific, and T...
|
| O: 7.76%
H: 26.67%
C: -8.67%
fda fda approval approval
FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy
Published: 2021-06-07 (Crawled : 14:00) - biospace.com/
MDT | News | $78.87 -0.27% 3.6M
|
Health Technology
|
| O: 0.44%
H: 0.6%
C: -0.35%
fda therapy fda approval approval
BioCelerate Continues to Help Improve Nonclinical Study Operations through Public Private Partnership with the FDA
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
NVO | News | $122.675 -1.49% 2.1M
|
Health Technology
|
| O: 0.59%
H: 0.59%
C: -0.28%
fda partnership
Cullinan Oncology Receives Investigational New Drug (IND) Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
CGEM | $18.2 1.79% 360K
|
|
| O: 0.27%
H: 4.48%
C: 1.99%
new drug treatment fda antibody drug clearance aml
bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
BLUE | $0.9551 -0.85% 4.5M
|
Health Technology
|
| O: 4.85%
H: 0.46%
C: -1.36%
disease fda clinical hold
OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland
Published: 2021-06-07 (Crawled : 12:00) - globenewswire.com
OPGN A | $0.581 -3.15% 160K
|
Commercial Services
|
| O: 2.42%
H: 7.4%
C: 5.66%
fda
Gainers vs Losers
| 72% | 28% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.